RxSight, Inc. Financial Summary

Quick Answer

RxSight, Inc. reported Total Revenue of $134.48 million for fiscal year 2025.

RxSight, Inc. — Key Financials by Year

Metric 2025 2024 2023 2022 2021 2020
Total Revenue $134.48M
-3.9%
$139.93M
+57.1%
$89.08M
+81.8%
$49.01M
+116.9%
$22.59M
+53.9%
$14.68M
Revenue (ASC 606) $134.48M
-3.9%
$139.93M
+57.1%
$89.08M
+81.8%
$49.01M
+116.9%
$22.59M
+53.9%
$14.68M
Net Income -$38.94M
-41.8%
-$27.45M
+43.5%
-$48.61M
+27.2%
-$66.76M
-37.1%
-$48.69M
-276.6%
$27.57M
Diluted EPS -$0.95
-33.8%
-$0.71
+49.6%
-$1.41
+41.5%
-$2.41
+32.5%
-$3.57
-2480.0%
$0.15
Total Assets $311.81M
-2.1%
$318.56M
+74.5%
$182.55M
+21.6%
$150.16M
-22.1%
$192.72M
+91.4%
$100.68M
Cash and Equivalents $19.95M
+19.4%
$16.71M
+72.4%
$9.69M
-18.1%
$11.83M
-51.4%
$24.36M
+74.1%
$13.99M
Long-Term Debt $0.00
-100.0%
$40.17M
+1.0%
$39.76M
+63.0%
$24.40M
Stockholders Equity $275.68M
-2.0%
$281.24M
+75.4%
$160.36M
+78.4%
$89.90M
-35.0%
$138.24M
+132.1%
-$430.59M
-2.6%
R&D Expense $38.55M
+12.2%
$34.37M
+18.3%
$29.05M
+11.8%
$25.98M
+6.0%
$24.50M
+11.7%
$21.93M
Operating Income -$48.19M
-30.7%
-$36.86M
+26.4%
-$50.09M
+20.9%
-$63.32M
-19.9%
-$52.79M
-49.1%
-$35.41M
Gross Profit $103.01M
+4.1%
$98.94M
+84.0%
$53.77M
+152.1%
$21.33M
+372.2%
$4.52M
+164.9%
$1.71M
Shares Outstanding 41.24M
+2.0%
40.43M
+11.9%
36.14M
+27.8%
28.27M
+3.3%
27.37M

Most Recent Quarter

Metric Quarter Ending Value YoY QoQ
Total Revenue September 30, 2025 $30.34M -14.1% -9.8%
Revenue (ASC 606) September 30, 2025 $30.34M -14.1% -9.8%
Net Income September 30, 2025 -$9.82M -54.9% +16.7%
Diluted EPS September 30, 2025 -$0.24 -50.0% +17.2%
Total Assets September 30, 2025 $308.53M -0.6% -0.2%
Cash and Equivalents September 30, 2025 $29.63M +77.2% -26.6%
Long-Term Debt September 30, 2023 $0.00 -100.0% -100.0%
Stockholders Equity September 30, 2025 $275.97M -0.5% -0.7%
R&D Expense September 30, 2025 $9.06M +2.5% -11.3%
Operating Income September 30, 2025 -$12.18M -32.0% +13.0%
Gross Profit September 30, 2025 $24.23M -3.9% -3.8%
Shares Outstanding September 30, 2025 41.08M +2.1% +0.4%
  • RxSight, Inc. reported Total Revenue of $134.48 million for fiscal year 2025.
  • RxSight, Inc. showed a decrease of -3.9% in Total Revenue compared to the prior fiscal year.
  • RxSight, Inc. reported Revenue (ASC 606) of $134.48 million for fiscal year 2025.
  • RxSight, Inc. showed a decrease of -3.9% in Revenue (ASC 606) compared to the prior fiscal year.
  • RxSight, Inc. reported Net Income of -$38.94 million for fiscal year 2025.
  • RxSight, Inc. showed a decrease of -41.8% in Net Income compared to the prior fiscal year.
  • RxSight, Inc. reported Diluted EPS of $0.95 per share (loss) for fiscal year 2025.
  • RxSight, Inc. showed a decrease of -33.8% in Diluted EPS compared to the prior fiscal year.
  • RxSight, Inc. reported Total Assets of $311.81 million for fiscal year 2025.
  • RxSight, Inc. showed a decrease of -2.1% in Total Assets compared to the prior fiscal year.
  • RxSight, Inc. reported Cash and Equivalents of $19.95 million for fiscal year 2025.
  • RxSight, Inc. showed an increase of +19.4% in Cash and Equivalents compared to the prior fiscal year.
  • RxSight, Inc. reported Long-Term Debt of $0.00 for fiscal year 2023.
  • RxSight, Inc. showed a decrease of -100.0% in Long-Term Debt compared to the prior fiscal year.
  • RxSight, Inc. reported Stockholders Equity of $275.68 million for fiscal year 2025.
  • RxSight, Inc. showed a decrease of -2.0% in Stockholders Equity compared to the prior fiscal year.
  • RxSight, Inc. reported R&D Expense of $38.55 million for fiscal year 2025.
  • RxSight, Inc. showed an increase of +12.2% in R&D Expense compared to the prior fiscal year.
  • RxSight, Inc. reported Operating Income of -$48.19 million for fiscal year 2025.
  • RxSight, Inc. showed a decrease of -30.7% in Operating Income compared to the prior fiscal year.
  • RxSight, Inc. reported Gross Profit of $103.01 million for fiscal year 2025.
  • RxSight, Inc. showed an increase of +4.1% in Gross Profit compared to the prior fiscal year.
  • RxSight, Inc. reported Shares Outstanding of 41.24 million shares for fiscal year 2025.
  • RxSight, Inc. showed an increase of +2.0% in Shares Outstanding compared to the prior fiscal year.
  • All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.

Last verified:

Leave a Comment